RUXOLITINIB
novartis,incyte
['rux,(-crux),(-trux),(-deruxtecan)', 'rux,(-crux),(-trux)']
congress #eha2023 | shares data from reach5, a phase ii trial of rux + cs for the treatment of pediatric patients with moderate to severe cgvhd. the treatment combination resulted in high orr at c7d1, a high bor up to c7d1 and an acceptable safety profile. #gvhdsm 
A global online platform providing latest treatment options and medical information in graft-versus-host disease (GvHD). #gvhd